Loading…
Penumbra, Inc. is projected to rise to $419.35 by 2027, a +32% move from its current price of $318.10. PEN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $315.66 | $318.27 | $320.91 | +0.05% |
| Jul 14 | $314.76 | $318.45 | $322.18 | +0.11% |
| Jul 15 | $314.10 | $318.62 | $323.21 | +0.16% |
| Jul 16 | $313.58 | $318.80 | $324.10 | +0.22% |
| Jul 17 | $313.14 | $318.97 | $324.91 | +0.27% |
| Jul 18 | $312.76 | $319.15 | $325.66 | +0.33% |
| Jul 19 | $312.43 | $319.32 | $326.37 | +0.38% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $312.43 | $319.32 | $326.37 | +0.38% |
| Week 2 | $310.81 | $320.55 | $330.59 | +0.77% |
| Week 3 | $309.84 | $321.78 | $334.17 | +1.16% |
| Week 4 | $309.22 | $323.01 | $337.43 | +1.55% |
| Week 5 | $308.81 | $324.26 | $340.47 | +1.94% |
| Week 6 | $308.56 | $325.50 | $343.37 | +2.33% |
| Week 7 | $308.42 | $326.75 | $346.17 | +2.72% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Penumbra, Inc. is a healthcare company that designs, develops, manufactures, and markets medical devices in the United States and internationally. Its product portfolio includes computer-assisted vacuum thrombectomy, peripheral thrombectomy devices such as the Indigo System for power aspiration of thrombus, Lightning Flash, Lightning Bolt 7, and CAT RX.
It also offers access products including guide catheters and distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25, MIDWAY, and PX SLIM brands, and the Penumbra System, an integrated mechanical thrombectomy system with reperfusion catheters and accessories under many Penumbra brands. In addition, Penumbra provides neuro embolization coils, peripheral embolization products, embolization platforms, microcatheters, occlusion devices, and related neurosurgical tools. The company was incorporated in 2004 and is based in Alameda, California, and it sells its products through direct sales organizations and distributors.
Penumbra, Inc. (PEN) is a healthcare stock currently priced at $317.20 per share, with a market capitalization of $12.48B. It holds the 807th rank by market cap among peers. The forecast pathway suggests upside potential over the long term, with the 2026 average price at $317.20 and the 2030 average at $532.73 (max $726.83) and the 2050 average at $2,274.58 (max $3,720.33).
The implied returns rise meaningfully in later years, with ROIs of 68% by 2030, 346% by 2040, and 617.1% by 2050, accompanied by a bullish overall sentiment in the later horizon.
A major floor 1.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.8% away) — a key level to hold.
Price is pressing into resistance (0.9% away) — a breakout level to watch.
A major ceiling 7.1% above — clearing it would confirm fresh momentum.
Key PEN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PEN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $317.97 | Buy | $317.84 | Buy |
| MA 10 | $317.27 | Buy | $317.64 | Buy |
| MA 20 | $317.37 | Buy | $318.05 | Buy |
| MA 50 | $320.75 | Sell | $320.91 | Sell |
| MA 100 | $327.83 | Sell | $321.29 | Sell |
| MA 200 | $310.80 | Buy | $311.04 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.63 | Neutral |
| Stoch RSI (14) | 93.14 | Sell |
| CCI (20) | 55.19 | Neutral |
| Williams %R (14) | -15.11 | Info |
| MACD (12,26,9) | 0.44 | Buy |
| ROC (12) | 0.15 | Buy |
| Bollinger %B (20,2) | 0.68 | Neutral |
| Stochastic %K (14) | 84.89 | Sell |
| TRIX (15) | -0.06 | Sell |
| Awesome (5,34) | -1.10 | Sell |
| Ultimate (7,14,28) | 64.20 | Neutral |
| Momentum (10) | 0.70 | Buy |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 318.14 | Sell |
| ADX (14) | 17.23 | Neutral |
| ATR (14) | 0.90 | Info |
The 30-day picture carries a bullish tilt in sentiment for the near term, supported by key levels and ranges. RSI(14) is 40, indicating neither overbought nor oversold pressure on a short horizon. The stock sits above the 200-day line and near the 50-day average, with the SMA50 at $324.44 and the SMA200 at $307.47.
Near-term support is at $316.16 and resistance at $328.69, framing a 30-day range from $300.10 to $335.27. Annualized volatility sits at 20%, reflecting elevated but manageable short-term variability.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $300.97 | $318.10 | $417.62 | 0% | Neutral | |
| $343.46 | $419.35 | $535.31 | +32% | Bullish | |
| $377.55 | $469.64 | $615.73 | +48% | Bullish | |
| $414.45 | $523.50 | $700.96 | +65% | Bullish | |
| $417.04 | $533.89 | $727.75 | +68% | Bullish | |
| $434.76 | $563.37 | $780.07 | +77% | Bullish | |
| $513.08 | $672.37 | $944.24 | +111% | Bullish | |
| $569.30 | $753.89 | $1,072.44 | +137% | Bullish | |
| $627.11 | $838.72 | $1,207.37 | +164% | Bullish | |
| $685.18 | $925.05 | $1,346.47 | +191% | Bullish | |
| $999.51 | $1,407.45 | $2,146.86 | +342% | Bullish | |
| $1,544.25 | $2,332.16 | $3,813.25 | +633% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $300.97 | $318.10 | $382.35 | +0.00% |
| August 2026 | $285.98 | $334.74 | $400.28 | +5.23% |
| September 2026 | $284.31 | $334.39 | $402.99 | -0.11% |
| October 2026 | $278.59 | $329.00 | $399.12 | -1.61% |
| November 2026 | $282.13 | $334.35 | $407.85 | +1.63% |
| December 2026 | $286.50 | $340.62 | $417.62 | +1.88% |
Click any year to see its month-by-month PEN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, PEN could reach as high as $417.62, with a base case around $318.10 and support toward $300.97 — roughly 0% from $318.10. Price action looks broadly range-bound.
Expect PEN to range from $343.46 to $535.31 through 2027. The $419.35 average target implies a +32% move from current prices. That is up +32% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The PEN price prediction for 2028 points to an average of $469.64 (low $377.55, high $615.73) — a potential gain of +48% on today's $318.10. Momentum favours further upside here.
In 2029, PEN is projected to trade between $414.45 and $700.96, averaging $523.50 — a potential gain of +65% from today's $318.10. That is up +11% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Penumbra, Inc.'s 2030 outlook centres on $533.89, within a $417.04 to $727.75 range. That is up +2% on the projected 2029 average. That marks a +68% change versus current levels. Momentum favours further upside here.
By 2031, PEN could reach as high as $780.07, with a base case around $563.37 and support toward $434.76 — roughly +77% from $318.10. Buyers look set to stay in control over this stretch.
Expect PEN to range from $513.08 to $944.24 through 2032. The $672.37 average target implies a +111% move from current prices. That is up +19% on the projected 2031 average. Momentum favours further upside here.
The PEN price prediction for 2033 points to an average of $753.89 (low $569.30, high $1,072.44) — a potential gain of +137% on today's $318.10. Buyers look set to stay in control over this stretch.
In 2034, PEN is projected to trade between $627.11 and $1,207.37, averaging $838.72 — a potential gain of +164% from today's $318.10. That is up +11% on the projected 2033 average. Momentum favours further upside here.
Penumbra, Inc.'s 2035 outlook centres on $925.05, within a $685.18 to $1,346.47 range. That is up +10% on the projected 2034 average. That marks a +191% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, PEN could reach as high as $2,146.86, with a base case around $1,407.45 and support toward $999.51 — roughly +342% from $318.10. Momentum favours further upside here.
Expect PEN to range from $1,544.25 to $3,813.25 through 2050. The $2,332.16 average target implies a +633% move from current prices. That is up +66% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in PEN today (≈ 3.143666 PEN) could be worth
$7,331.52
+$6,331.52 (+633%) by 2050 · US Dollar
Based on the average projected PEN price of $2,332.16 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PENwould be worth at today's price.
$1,000 invested in PEN on Jul 10, 2025 (≈ 4.100545 PEN) would be worth
$1,304.38
+$304.38 (+30.4%) today · 1.30× · US Dollar
Based on a PEN entry price of $243.87 vs. today's $318.1.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $318.57 | $998.52 | -0.1% |
| 1 month ago | $319.34 | $996.12 | -0.4% |
| 3 months ago | $329.77 | $964.61 | -3.5% |
| 6 months ago | $319.47 | $995.71 | -0.4% |
| 1 year ago | $243.87 | $1,304.38 | +30.4% |
| All time (5.0y) ago | $264.11 | $1,204.42 | +20.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PEN forecast.
Our base-case forecast reaches $640.00 around 2032.
Implied market cap at $640.00: $25.17B
The multi-year forecast outlines a sustained growth trajectory with rising average prices and expanding upside. By 2030, the average price is projected at $532.73 with a 68% ROI, and the max reaches $726.83, underscoring a meaningful long-run upside. By 2040 the average climbs to $1,414.68 with a 346% ROI and a max of $2,158.87, indicating substantial long-term upside potential even after a long lead time.
By 2050 the average is projected to $2,274.58 with a 617.1% ROI and a max of $3,720.33, suggesting a pronounced long-horizon appreciation potential. Across the mid-to-late forecast years, sentiment is shown as BULLISH, with ROIs expanding from 0% in 2026 to substantial double- to triple-digit figures in later years. These are estimates and not guarantees; actual results will depend on factors and conditions that can change over time.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $532.73, with a min of $415.85 and a max of $726.83; ROI 68%. These numbers are estimates and not guaranteed.
The forecast indicates bullish sentiment from 2027 onward, with an average price of $532.73 by 2030 and $2,274.58 by 2050, and ROIs of 68% by 2030 and 617.1% by 2050. These are estimates, not guarantees.
Yes. The max forecast reaches $1,333.59 by 2035 and $2,158.87 by 2040, indicating the possibility of surpassing $1,000 within the horizon.
The 2040 forecast shows an average price of $1,414.68, a min of $1,004.22, and a max of $2,158.87, with a 346% ROI. The sentiment is bullish.
Current price is $317.20 per share and the market capitalization is $12.48B.
Penumbra, Inc. Community Discussion
0Share your Penumbra, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.